Gene mutations in esophageal mucosa of chagas disease patients

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1243-1248

  Manoel Caetano, Fernanda DA Silva ^a   Silveira, Aparecida F P ^a   Silva, Ana Elizabete ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Cdkn2a gene; Chagas disease; Dna sequencing; Fhitgene; Megaesophagus, gene mutation; Single nucleotide polymorphism (snp); Tp53 gene

Indexed keywords

ADULT; AGED; ARTICLE; CARCINOGENESIS; CHAGAS DISEASE; CLINICAL ARTICLE; DNA SEQUENCE; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; EXON; FEMALE; GENE MUTATION; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ACID ANHYDRIDE HYDROLASES; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHAGAS DISEASE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 64949187915     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Wychulis AR, Woolam GL, Andersen HA and Ellis FH Jr: Achalasia and carcinoma of the esophagus. JAMA 215: 1638- 1641,1971.
2. Briicher BLDM, Stein HJ, Battels H, Feussner H and Siewert JR: Achalasia and esophageal cancer: incidence, prevalence, and prognosis. World J Surg 25: 745-749, 2001.
3. Henry MAC de A, Lerco MM and de Oliveira WK: Câncer do esôfago em paciente com megaesôfago chagásico. Arq Gastroenterol 44: 151-153,2007.
4. Pajecki D, Zilberstein B, dos Santos MAA, Quintanilha AG, Cecconello I and Gama-Rodrigues J: Microbiota do megaesôfago e carcinogenese. Arq Gastroenterol 40: 16-19, 2003.
5. Chino O, Kijima H, Shimada H, Nishi T, Tanaka H, Oshiba G, Kise Y, Kajiwara H, Tsuchida T, Tanaka M, Tajima T and Makuuchi H: Clinicopathological studies of esophageal carcinoma in achalasia: analyses of carcinogenesis using histological and immunohistochemical procedures. Anticancer Res 20: 3717-3722, 2000.
6. Vespúcio MVO, Paschoal RM, Zucoloto S, Garcia, FRB, Dalio MB, Soares EG and Garcia SB: A new experimental model to study preneoplastic lesions in achalasia of the esophagus. Acta Cir Brás 20: 418-824, 2005.
7. Pajecki D, Zilberstein B, Santos MAA dos, Ubriaco JA, Quintanilha AG, Cecconello I and Gama-Rodrigues J: Megaesophagus Microbiota: a qualitative and quantitative analysis. J Gastrointest Surg 6: 723-729, 2002.
8. Fujii T, Yamana H, Sueyoshi S, Fujita H, Tanaka Y, Kubota M, Toh U, Mine T, Sasahara H, Shirouzu K, Kato S and Morimatsu M: Histopathological analysis of non-malignant and malignant epithelium in achalasia of the esophagus. Dis Esophagus 13: 110-116, 2000.
9. Lehman MB, Clark SB, Ormsby AH, Rice TW, Richter JE and Goldblum JR: Squamous mucosal alterations in esophagectomy specimens from patients with end-stage achalasia. Am J Surg Pathol 25: 1413-1418, 2001.
10. Bektas A, Yasa MH, Kuzu I, Dogan I, Unal S and Ormeci N: Flow cytometric DNA analysis, and immunohistochemical p53, PCNA and histopathologic study in primary achalasia: preliminary results. Hepatogastroenterology 48: 408-412, 2001.
11. Rezende, J, Lauar, KM and de Oliveira, A: Clinical and radiological aspects of aperistalsis of the esophagus. Rev Bras Gastroenterol 12: 247-262, 1960.
12. Maniatis T, Fritsch, EF and Sambrook J. Molecular cloning: a laboratory manual. New York, Cold Spring Harbor Laboratory Press, 1989.
13. Hall TA: BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41: 95-98, 1999.
14. Safatle-Ribeiro AV, Ribeiro U Jr, Sakai P, Clarke MR, Fylyk SN, Ishioka S, Gama-Rodrigues J, Finkelstein SD and Reynolds JC: Integrated p53 histopathologic/genetic analysis of premalignant lesions of the esophagus. Cancer Detect Prevent 24: 13-23, 2000.
15. Kannan K, Munirajan AK, Bhuvarahamurthy V, Mohanprasad BKC, Shankar P and Shanmugam G: FHIT gene mutations and single nucleotide polymorphism in Indian oral and cervical squamous cell carcinomas. Oral Oncol 36: 189-193, 2000.
16. Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H, Croce CM and Huebner K: Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 57: 504-512, 1997.
17. Wang J, Smith PJ, Krainer AR and Zang MQ: Distribution of SR protein exonic splicing enhancer motifs in human protein-coding genes. Nucleic Acids Res 33: 5053-5062, 2005.
18. Mao L, Fan YH, Lotan R and Hong WK: Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell line. Cancer Res 56: 5128-5131, 1996.
19. Zou TT, Lei J, Shi YQ, Yin J, Wang S, Souza RF, Kong D, Shimada Y, Smolinski KN, Greenwald BD, Abraham JM, Harpaz N and Meltzer SJ: FHIT gene alterations in esophageal cancer and ulcerative colitis (UC). Oncogene 15: 101-105, 1997.
20. + and RER-adenocarcinomas of the pancreas. Genes Chromosomes Cancer 27: 239-243, 2000.
21. Cecener G, Egeli Ü, Tunca B, Tas I, Tolunay S and Bilgel N: Importance of novel sequence alterations in the FHIT gene on formation of breast cancer. Tumori 93: 597-603, 2007.
22. Thi Tran HT, Takeshima Y, Surono A, Yagi M, Wada H and Matsuo M: A G-to-A transition at the fifth position of intron-32 of the dystrophin gene inactivates a splice-donor site both in vivo and in vitro. Mol Genet Metab 85: 213-219, 2005.
23. Fackenthal JD, Cartegni L, Krainer AR and Olopade OI: BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet 71: 625-631, 2002.
24. Yang Y, Swaminathan S, Martin BK and Sharan SK: Aberrant splicing induced by missense mutations in BRCAI. clues from a humanized mouse model. Hum Mol Genet 12: 2121-2131, 2003.
25. Valcarcel J and Green MR: The SR protein family: pleiotropic functions in pre-mRNA splicing. Trends Biochem Sci 21: 296- 301, 1996.
26. Kitamura A, Yashima K, Okamoto E, Andachi H, Hosoda A, Kishimoto Y, Shiota G, Ito H, Kaibara N and Kawasaki H: Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology 61: 205-211, 2001.
27. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W and Diatchenko L: Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314: 1930-1933, 2006.
28. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV and Gottesman MM: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525- 528, 2007.
29. Tsai CJ, Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM and Nussinov R: Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. Mol Biol 383: 281-291, 2008.
30. Ishii H, Wang Y and Huebner K: A Fhit-ing role in the DNA damage checkpoint response. Cell Cycle 6: 1044-1048, 2007.
31. Pichiorri F, Palumbo T, Suh SS, Okamura H, Trapasso F, Ishii H, Huebner K and Croce CM: Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol 4: 815-824, 2008
32. Manoel-Caetano FS, Borim AA, Caetano A, Cury PM and Silva AE: Cytogenetic alterations in chagasic achalasia compared to esophageal carcinoma. Cancer Genet Cytogenetics 149: 17-22, 2004.
33. Duesberg PH: Are cancers dependent on oncogenes or on aneuploidy? Cancer Genet Cytogenet 143: 89-91, 2003.